- Condition: Osteoarthritis
Interventions: Other: Hospital Inpatient Rehabilitation; Other: Hybrid Home Programme (HO)
Sponsors: South West Sydney Local Health District; Mark Buhagiar; HammondCare
Not yet recruiting - verified April 2012 - Conditions: Scleroderma, Systemic; Sclerosis, Systemic; Systemic Scleroderma; Systemic Sclerosis
Interventions: Drug: Pomalidomide (CC-4047); Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Not yet recruiting - verified April 2012 - Conditions: Greater Trochanteric Pain Syndrome; Hip Pain
Interventions: Device: Topaz; Procedure: Iliotibial band release and trochanteric bursectomy
Sponsors: ArthroCare Corporation; ArthroCare Corporation
Not yet recruiting - verified February 2012 - Condition: Gout
Interventions: Drug: lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: Adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Optimus Clinical Research; Optimus Clinical Research; Arthritis Australia, Abbott Australia
Recruiting - verified November 2011 - Condition: Osteoarthritis of the Knee
Interventions: Drug: FX006; Drug: Commercially available triamcinolone acetonide
Sponsors: Flexion Therapeutics, Inc.; Flexion Therapeutics, Inc.
Not yet recruiting - verified May 2012 - Condition: Arthritis, Psoriatic
Interventions: Biological: Placebo matching BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Osteoarthritis of the Knee
Interventions: Drug: FX006; Drug: commercially available triamcinolone acetonide
Sponsors: Flexion Therapeutics, Inc.; Flexion Therapeutics, Inc.
Not yet recruiting - verified May 2012 - Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2012 - Condition: Juvenile Idiopahtic Arthritis
Intervention: Drug: etanercept
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Chronic Gouty Arthritis
Intervention: Biological: canakinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Psoriatic Arthritis
Interventions: Biological: Secukinumab (75 mg); Biological: Secukinumab (150 mg); Biological: Placebo Comparator
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Gout
Intervention: Drug: Allopurinol
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Fostamatinib; Drug: Fostamatinib; Drug: Fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: LY2127399
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 4 weeks; Drug: Placebo every 2 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 4 weeks; Drug: Placebo every 2 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: fostamatinib; Drug: fostamatinib; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Methotrexate; Drug: Abatacept Placebo; Drug: Methotrexate Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Anterior Cruciate Ligament Injury; Osteoarthritis
Interventions: Biological: MSB-CAR001 Combined With Hyaluronan; Drug: Hyaluronan
Sponsors: Mesoblast, Ltd.; Mesoblast, Ltd.
Recruiting - verified March 2010 - Condition: Degenerative Arthritis of Knee
Interventions: Other: Total Knee Arthroplasty; Other: Total Knee Arthroplasty
Sponsors: Smith & Nephew, Inc.; Smith & Nephew, Inc.
Recruiting - verified November 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: SAR153191 (REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Condition: Osteoarthritis, Hip
Intervention:
Sponsors: Smith & Nephew, Inc.; Smith & Nephew, Inc.
Recruiting - verified July 2011 - Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque PsoriasisConditions: Arthritis, Psoriatic; Psoriasis
Intervention: Other: questionnaire
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Chronic Allograft Nephropathy; Chronic Kidney Disease; Chronic Renal Failure; Disordered Mineral Metabolism; End Stage Renal Disease; Hyperparathyroidism; Hypophosphatemia; Kidney Disease; Kidney Transplantation; Post Renal Transplantation
Interventions: Drug: Cinacalcet; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; Kirby Institute; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified April 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2012
 |
Join Clinical Trials in Matanuska-Susitna,Alaska |
